Related Experiment Videos
[Primary metastasized hypernephroma: therapy and follow-up]
V G Hienert1, D Latal, J Kühböck
1Urologische Universitätsklinik Wien.
Zeitschrift Fur Urologie Und Nephrologie
|December 1, 1987
Summary
For patients with metastatic renal cell carcinoma, removing the primary tumor did not significantly impact survival rates when compared to not removing it. Chemotherapy also showed no significant survival benefit in this patient group.
Area of Science:
- Oncology
- Urology
Context:
- Disseminated renal cell carcinoma presents a significant clinical challenge.
- Treatment decisions for metastatic renal cell carcinoma often involve nephrectomy and chemotherapy.
Purpose:
- To evaluate the impact of nephrectomy and chemotherapy on survival in patients with disseminated renal cell carcinoma.
Summary:
- This study analyzed 44 patients with disseminated renal cell carcinoma, comparing outcomes between those who underwent nephrectomy (24 patients) and those who did not (20 patients).
- Chemotherapy was administered to 12 patients (7 in the nephrectomy group, 5 in the non-nephrectomy group).
- No significant difference in survival rates was observed between patients who received chemotherapy and those who did not, nor was there a significant difference based on nephrectomy status. Partial response to chemotherapy was limited and short-lived.
Impact:
- The findings suggest that current chemotherapy regimens may have limited efficacy in improving survival for patients with metastatic renal cell carcinoma.
- Further research is needed to determine the optimal role of chemotherapy and nephrectomy in managing disseminated renal cell carcinoma.